The Türkiye Heart Failure Registry

NCT06707220 | Recruiting

• 1 other identifier: KA23/429
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

A comprehensive understanding of the socio-demographic, clinical, and biological characteristics of patients with heart failure is essential to develop novel strategies for improving outcomes. The identification of the barriers to guideline-directed medical therapy implementation in a real-world setting is critical to decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient, physician, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy. It should be noted that the number of heart failure registries that enroll patients with de novo heart failure, chronic heart failure (outpatients), and worsening of heart failure (hospitalized or treated in the emergency department), with all three relevant ejection fraction categories (heart failure with reduced ejection fraction, heart failure with mildly-reduced ejection fraction, and heart failure with preserved ejection fraction), is limited. Furthermore, only a few registries assess detailed aspects of guideline adherence, treatment decisions, and both in-hospital and long-term outcomes. Therefore, the Türkiye Heart Failure (TURK-HF) registry has been designed to address this gap in knowledge about the identification, management, and long-term prognosis of patients with heart failure in a real-world setting.

Conditions

Heart Failure

Outcome Measures

Primary Outcomes (3)

• Heart failure hospitalization

  From enrollment to the end of follow-up period at 12 months

• Cardiovascular mortality

  From enrollment to the end of follow-up period at 12 months

• Composite of heart failure hospitalization and cardiovascular mortality

  From enrollment to the end of follow-up period at 12 months

Secondary Outcomes (1)

• All-cause mortality

  From enrollment to the end of follow-up period at 12 months

Interventions

Heart failure medication OTHER

Treated with optimal guideline-directed medical therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The only inclusion criterion for the Türkiye Heart Failure (TURK-HF) registry is the presence of heart failure, as determined by an investigator, and the only exclusion criterion is age \<18 years. All patients will be eligible for enrollment regardless of their ejection fraction and whether they have pre-existing chronic or de novo heart failure. All patients will be enrolled in the study, regardless of their clinical status. This encompasses both those presenting for a non-urgent outpatient visit with stable signs and symptoms and those requiring urgent care with worsening of heart failure. Worsening heart failure is defined as worsening symptoms and signs of heart failure in patients with pre-existing heart failure, requiring hospitalization and/or intravenous diuretic therapy. All study participants must provide written informed consent.

Sponsors & Collaborators

• Baskent University: lead

Study Sites (1)

Baskent University

Ankara, Ankara, 0600, Turkey (Türkiye)

RECRUITING

Related Publications (3)

• Kocabas U, Ergin I, Yavuz V, Altin C, Kaplan M, Yilmaz Oztekin GM, Dogdus M, Murat S, Murat B, Kivrak T, Karabulut D, Kaya E, Ozdemir IH, Yildiz C, Salkin FO, Ozcalik E, Polatkan SG, Cakan F, Sen T, Karabulut U, Cakal S, Oflar E, Sinan UY, Yenercag M, Turk UO. Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study. ESC Heart Fail. 2025 Feb;12(1):434-446. doi: 10.1002/ehf2.15049. Epub 2024 Sep 28.

  PMID: 39340234 BACKGROUND

• Kocabas U, Ergin I, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir I, Avci Demir F, Dogdus M, Sen T, Altinsoy M, Ustundag S, Urgun OD, Sinan UY, Uygur B, Yeni M, Ozcalik E. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2023 Dec;10(6):3677-3689. doi: 10.1002/ehf2.14559. Epub 2023 Oct 7.

  PMID: 37804042 BACKGROUND

• Kocabas U, Kivrak T, Yilmaz Oztekin GM, Tanik VO, Ozdemir IH, Kaya E, Yuce EI, Avci Demir F, Dogdus M, Altinsoy M, Ustundag S, Ozyurtlu F, Karagoz U, Karakus A, Urgun OD, Sinan UY, Mutlu I, Sen T, Astarcioglu MA, Kinik M, Tok OO, Uygur B, Yeni M, Alan B, Dalgic O, Sariturk C, Altay H, Pehlivanoglu S. Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study. Anatol J Cardiol. 2020 Jul;24(1):32-40. doi: 10.14744/AnatolJCardiol.2020.91771.

  PMID: 32628147 BACKGROUND

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Central Study Contacts

Umut Kocabaş

CONTACT

+905079974999; umutkocabas@hotmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Medical Doctor

Study Record Dates

• First Submitted: November 24, 2024
• First Posted: November 27, 2024
• Study Start: January 8, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: March 3, 2025

Record last verified: 2025-02

Locations

TU (1)